Navigation Links
Reportlinker Adds Advanced Lung Cancer in Patient Smoker with Squamous Cell: Clinical Insights from a US Oncologists' Survey
Date:4/28/2011

NEW YORK, April 28, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p0487248/Advanced-Lung-Cancer-in-Patient-Smoker-with-Squamous-Cell-Clinical-Insights-from-a-US-Oncologists-Survey.html

Advanced Lung Cancer in Patient Smoker with Squamous Cell: Clinical Insights from a US Oncologists' Survey

A patient specific case scenario on advanced lung cancer in a situation involving a smoker with squamous cell that progresses throughout the report, presented to 158 high-prescribing oncologists for their open responses on clinical decisions. Patient progression reveals:

• Decisions in treatment and tests through disease stages

• Factors influencing their decisions

• Barriers to optimal care

• Confidence in treatment.

Data has been synthesized to show all responses and direct quotes from the oncologists. This is the primary research for the oncology prescribing data that you are missing - directly from high-prescribing US oncologists on Advanced Lung Cancer.

Treatment decisions for advanced stages of breast cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists' choices. This report is part of a series of oncology reports that allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer.

This report allows you to:

• Understand what occurs with actual patients

• Access the most up-to-date prescribing trends

• Gain actionable data for developing and improving your market strategies

• Pinpoint needs of your target audience

• Focus resources to maximize the effectiveness of your budget

• Understand where your product fits

• Understand where your competitor's product fits

• Design messages to advance brand performance

Table of Contents

Executive Summary5

Chapter 1: Introduction7

Table 1: Treatment Options in Advanced Lung Cancer7

Chapter 2: Respondent Demographics9

Table 2: Eligibility Criteria for Survey Participation9

Figure 2.1 Gender of Survey Respondents9

Figure 2.2 Years since Medical School Graduation10

Figure 2.3 Practice Settings10

Figure 2.4 Practices in NCI Cancer Centers11

Figure 2.5 Geographic Settings11

Figure 2.6 Survey Respondents by State's Lung Cancer Mortality12

Figure 2.7 Number of Physicians in Practice Groups13

Figure 2.8 Minimal Acceptable Level of Evidence in Determining Treatment Regimen13

Chapter 3: Treatment of a Smoker with Squamous Cell Carcinoma14

Figure 3.1 Laboratory studies to be done on the tumor tissue14

Figure 3.2 First line chemotherapy regimen15

Figure 3.3 Factors Influencing Treatment Decisions16

Figure 3.4 Confidence in treating this patient to an optimal outcome18

Figure 3.5 Next step in management19

Figure 3.6 Subsequent treatment regimen21

Figure 3.7 Treatment at next cancer progression22

Figure 3.8 Factors influencing treatment decisions23

Figure 3.9 Barriers to management of advanced lung cancer25

Chapter 4: Summary27

Appendix A: Survey Instrument29

Companies mentioned

Eli Lilly, Genentech/Roche, Bristol-Myers Squibb, Glaxo Smith Kline, Pfizer, Sanofi-aventis

To order this report:

:

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Advanced Lung Cancer with EGFR Mutation Positive Adenocarcinoma
2. Reportlinker Adds Pharmaceutical Key Trends 2011 - Prescription Pharmaceutical Sales Overview
3. Reportlinker Adds Pharmaceutical Key Trends 2011 - Healthcare System and Drug Regulatory Overview: Cost-containment and regulatory pressures intensify
4. Reportlinker Adds Pharmaceutical Key Trends 2011 - Biosimilar Market Overview
5. Reportlinker Adds Pharmaceutical Key Trends 2011 - Brand Erosion Post-Patent Expiry
6. Reportlinker Adds Forecast Insight: Antibacterials
7. Reportlinker Adds Global Cardiovascular Surgery Devices Market Trends and Future Forecast (2009 - 2014)
8. Reportlinker Adds European Smart Homes and Assisted Living Market (2010-2015)
9. Reportlinker Adds The Outlook for Pharmaceuticals in Latin America
10. Reportlinker Adds Global Respiratory Care Devices Market (2010 - 2015)
11. Reportlinker Adds Orphan Drugs in Asia: Guidelines and Regulatory Requirements to Help Orphan Drug Products Enter the Asian Market 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... -- Endo International plc (NASDAQ: ENDP ) ... Joseph R. Goodwin , U.S. District Court Judge for ... , entered a case management order in MDL 2325, ... Litigation (the "MDL") that includes a provision requiring plaintiffs ... on specific causation within one hundred twenty (120) days ...
(Date:6/3/2017)... 2017  Eli Lilly and Company (NYSE: ... the Phase 3 MONARCH 2 study showed that ... in combination with fulvestrant, significantly improved progression-free survival ... women with hormone-receptor-positive (HR+), human epidermal growth factor ... relapsed or progressed after endocrine therapy (median PFS, ...
(Date:5/30/2017)... AVIV, Israel , May 30, 2017 ... stage pharmaceutical Company specializing in the development of ... will present a company overview at three upcoming ... The 7th Annual LD Micro Invitational: ... Date:                     ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... June 23, 2017 , ... Radabaugh & Associates, a locally ... business owners in North Central West Virginia, is embarking on a cooperative charity ... residents in the region. , The Stepping Stones organization offers a series of ...
(Date:6/22/2017)... ... 2017 , ... Plastic Surgery Associates is proud to report that founding surgeon, ... research and information firm, Castle Connolly, releases their list of the most notable and ... 3rd time that Dr. Canales has been recognized by Castle Connolly. , ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... from the American Heart Association (AHA) to launch a Rheumatic Heart Disease Center, ... prevention and diagnosis of rheumatic heart disease (RHD) in high-risk, financially disadvantaged countries ...
(Date:6/22/2017)... , ... June 22, 2017 , ... ... announced today that it has received certification for ANSI/ASIS PSC.1-2012. The company’s work ... in environments where the rule of law has been degraded. The PSC.1 standard ...
(Date:6/20/2017)... ... June 20, 2017 , ... TwelveStone Health Partners, ... a Nashville-based private equity firm, has invested $3.35 million in the company. ... and Claritas Capital offers the smart money, speed to market and accountability we ...
Breaking Medicine News(10 mins):